Intra-Cellular Therapies, Inc.


SKU: ITCI Category:


Intra-Cellular Therapies, Inc.: Initiation Of Coverage


This is our first report on biopharma major, Intra-Cellular Therapies. The company reported solid progress in its Q4 and FY2023 results, marking a year characterized by steady growth across the company. Central to the year’s success was the establishment of CAPLYTA as a vital treatment option for bipolar depression and schizophrenia. The company reported total revenues of $464 million for 2023, signaling an 86% increase in CAPLYTA net sales from the previous year. Prescription growth was driven by well-executed commercial efforts from both new and existing prescribers.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!